Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis ...

The US FDA has approved ruxolitinib (Opzelura) cream 1.5% for the short-term and noncontinuous chronic treatment of ...

The serum is noncomedogenic and oil-free. It does contain fragrance, but many reviewers called the scent “subtle” and “lovely ...

Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...

Men's skin needs specific care. This article highlights common skin problems faced by men. Dryness, shaving irritation, dark circles, oily skin, and a ...

Rosacea can cause redness, breakouts, and discomfort. Here, dermatologists share moisturizers that may help color-correct ...